Novo Nordisk has halted the CLARION-CKD trial due to unmet primary endpoints and will recognize an impairment loss of approximately DKK 5.7 billion. This event, reported on June 26, 2024, represents a negative impact of around 6 percentage points on operating profit growth for 2024.